Share on StockTwits

BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II unloaded 3,125 shares of the stock on the open market in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.00, for a total transaction of $40,625.00. Following the completion of the sale, the chief financial officer now directly owns 144,301 shares in the company, valued at approximately $1,875,913. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down 1.87% on Thursday, hitting $12.62. The stock had a trading volume of 333,546 shares. BioCryst Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $13.33. The stock’s 50-day moving average is $10.62 and its 200-day moving average is $9.96. The company’s market cap is $758.0 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Thursday, May 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the analysts’ consensus estimate of ($0.17). The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter last year, the company posted ($0.09) earnings per share. BioCryst Pharmaceuticals’s revenue was down 2.8% compared to the same quarter last year. Analysts expect that BioCryst Pharmaceuticals will post $-0.75 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Wells Fargo & Co. upgraded shares of BioCryst Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, June 23rd. They now have a $17.00 price target on the stock, down previously from $19.00. Separately, analysts at HC Wainwright raised their price target on shares of BioCryst Pharmaceuticals from $21.00 to $24.00 in a research note on Friday, May 30th. They now have a “buy” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of BioCryst Pharmaceuticals from $18.00 to $20.00 in a research note on Wednesday, May 28th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $18.13.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.